Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Autor: Arvind Gharbharan, Carlijn C. E. Jordans, Corine GeurtsvanKessel, Jan G. den Hollander, Faiz Karim, Femke P. N. Mollema, Janneke E. Stalenhoef – Schukken, Anthonius Dofferhoff, Inge Ludwig, Adrianus Koster, Robert-Jan Hassing, Jeannet C. Bos, Geert R. van Pottelberge, Imro N. Vlasveld, Heidi S. M. Ammerlaan, Elena M. van Leeuwen – Segarceanu, Jelle Miedema, Menno van der Eerden, Thijs J. Schrama, Grigorios Papageorgiou, Peter te Boekhorst, Francis H. Swaneveld, Yvonne M. Mueller, Marco W. J. Schreurs, Jeroen J. A. van Kampen, Barry Rockx, Nisreen M. A. Okba, Peter D. Katsikis, Marion P. G. Koopmans, Bart L. Haagmans, Casper Rokx, Bart J. A. Rijnders

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)

There are currently no drugs available to treat SARS-CoV-2 infection. A promising alternative treatment for COVID-19 patients is convalescent plasma. Here, Gharbharan et al. collect covalescent plasma and report no overall clinical benefit for 86 pat

Externí odkaz: https://doaj.org/article/a6dfe323ebd74308ad646da02ba72d20

Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine

Autor: Sander van Assen, Hazra S. Moeniralam, Jacqueline Buijs, Renée A. Douma, Joop P. W. van den Bergh, Abraham Goorhuis, Wouter de Ruijter, Edgar J G Peters, R. Renckens, Didier Collard, Martijn Beudel, Paul W. G. Elbers, Lieve G. Hh. Knarren, Lianne de Haan, Rémy L M Mostard, Niels C. Gritters van den Oever, Auke C Reidinga, Imro N. Vlasveld, Marije K. Bomers, Marian J. R. Quanjel, Jonne J. Sikkens

Publikováno v: CovidPredict Study Group 2021, ' Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine ', Clinical Microbiological and Infection, vol. 27, no. 2, pp. 264-268 . https://doi.org/10.1016/j.cmi.2020.10.004
Clinical microbiology and infection, 27(2), 264-268. Elsevier Limited
Clinical Microbiological and Infection, 27(2), 264-268
Clinical Microbiology and Infection

OBJECTIVE: To compare survival of individuals with coronavirus disease 2019 (COVID-19) treated in hospitals that either did or did not routinely treat patients with hydroxychloroquine or chloroquine.METHODS: We analysed data of COVID-19 patients trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::927a6eeb880a83e3c7c08033ab92d387
https://research.vumc.nl/en/publications/ab1a5fb5-badb-4222-99b7-e9d97f5c5281

Fecal Microbiota Transfer for Multidrug-Resistant Gram-Negatives: A Clinical Success Combined With Microbiological Failure

Autor: Peter van ‘t Hof, Leo G. Visser, Josbert J. Keller, Elisabeth M. Terveer, Cornelis W. Knetsch, Janneke E. Stalenhoef, E.J. Kuijper, Imro N. Vlasveld

Publikováno v: Open Forum Infectious Diseases
Open Forum Infectious Diseases, 4(2)

Combined fecal microbiota transfer and antibiotic treatment prevented recurrences of urinary tract infections with multidrug-resistant (MDR) Pseudomonas aeruginosa, but it failed to eradicate intestinal colonization with MDR Escherichia coli. Based o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebe8e043befa67fd574113aabee042ff
https://pubmed.ncbi.nlm.nih.gov/28470023